Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

European Urology
G GravisChristopher J Sweeney

Abstract

Docetaxel (D) at the time of starting androgen deprivation therapy (ADT) for metastatic castrate naive prostate cancer shows a clear survival benefit for patients with high-volume (HV) disease. It is unclear whether patients with low-volume (LV) disease benefit from early D. To define the overall survival (OS) of aggregate data of patient subgroups from the CHAARTED and GETUG-AFU15 studies, defined by metastatic burden (HV and LV) and time of metastasis occurrence (at diagnosis or after prior local treatment [PRLT]). Data were accessed from two independent phase III trials of ADT alone or ADT+D-GETUG-AFU15 (N=385) and CHAARTED (N=790), with median follow-ups for survivors of 83.2 and 48.2 mo, respectively. The definition of HV and LV disease was harmonized. The primary end point was OS. Meta-analysis results of the aggregate data showed significant heterogeneity in ADT+D versus ADT effect sizes between HV and LV subgroups (p=0.017), and failed to detect heterogeneity in ADT+D versus ADT effect sizes between upfront and PRLT subgroups (p=0.4). Adding D in patients with HV disease has a consistent effect in improving median OS (HV-ADT: 34.4 and 35.1 mo, HV-ADT+D: 51.2 and 39.8 mo in CHAARTED and GETUG-AFU15, respectively; pooled ...Continue Reading

Citations

Jul 18, 2018·Current Opinion in Supportive and Palliative Care·Zineb HamilouKarim Fizazi
Sep 7, 2018·BJU International·Nicholas D James
Oct 16, 2018·The Cochrane Database of Systematic Reviews·Niranjan J SathianathenPhilipp Dahm
Jan 16, 2019·The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutica·Daniele G NicolottiDésirée Deandreis
Nov 22, 2018·International Journal of Urology : Official Journal of the Japanese Urological Association·Masaki ShiotaMasatoshi Eto
Jul 25, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B P S BelderbosR J van Soest
Mar 18, 2020·American Society of Clinical Oncology Educational Book·Brian SchulteCarmel Pezaro
May 20, 2020·Current Opinion in Urology·Catalin BastonConstantin Gingu
May 15, 2020·Expert Review of Anticancer Therapy·Jeanny B Aragon-Ching, Robert Dreicer
Jul 20, 2019·Nature Reviews. Urology·Ryan P Kopp, Tomasz M Beer
May 27, 2020·Current Opinion in Urology·Constantin GînguCătălin Baston
Aug 20, 2019·Future Oncology·Orazio CaffoCarlo Messina
Jan 4, 2020·World Journal of Urology·E M KwanA A Azad
Jun 4, 2019·The New England Journal of Medicine·Ian D DavisUNKNOWN ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
May 27, 2020·Current Opinion in Urology·Nicolai A HuebnerGero Kramer
Feb 16, 2019·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Matthias Guckenberger
Nov 28, 2020·Expert Review of Anticancer Therapy·Orazio CaffoCarlo Messina
Mar 30, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Konrad H StopsackWassim Abida
Jan 22, 2021·Expert Review of Anticancer Therapy·Sympascho YoungGlenn Bauman
Jan 27, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katherine S VirgoJames Talcott
Jul 16, 2020·Clinical Genitourinary Cancer·Giandomenico RovielloAlberto D'Angelo
Mar 7, 2021·Diagnostics·Ciara S McNevinStephen P Finn
Oct 1, 2018·Urologic Oncology·Igor TsaurUNKNOWN EAU-YAU Prostate Cancer Working Party
Apr 16, 2021·Expert Opinion on Pharmacotherapy·Jason ShpilskyGlenn Bubley
Dec 23, 2020·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·F RozetA Méjean

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.